Northern Trust’s Translate Bio, Inc. Common Stock TBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-698,620
| Closed | -$19.2M | – | 4785 |
|
|
2021
Q2 | $19.2M | Sell |
698,620
-39,572
| -5% | -$778K | ﹤0.01% | 1911 |
|
|
2021
Q1 | $12.2M | Sell |
738,192
-31,795
| -4% | -$724K | ﹤0.01% | 2169 |
|
|
2020
Q4 | $14.2M | Sell |
769,987
-11,248
| -1% | -$201K | ﹤0.01% | 2037 |
|
|
2020
Q3 | $10.6M | Buy |
781,235
+325,611
| +71% | +$5.02M | ﹤0.01% | 2077 |
|
|
2020
Q2 | $8.16M | Buy |
455,624
+12,417
| +3% | +$187K | ﹤0.01% | 2223 |
|
|
2020
Q1 | $4.42M | Buy |
443,207
+33,115
| +8% | +$271K | ﹤0.01% | 2378 |
|
|
2019
Q4 | $3.34M | Buy |
410,092
+72,906
| +22% | +$673K | ﹤0.01% | 2824 |
|
|
2019
Q3 | $3.34M | Buy |
337,186
+26,940
| +9% | +$254K | ﹤0.01% | 2791 |
|
|
2019
Q2 | $3.92M | Buy |
310,246
+21,593
| +7% | +$228K | ﹤0.01% | 2684 |
|
|
2019
Q1 | $2.94M | Buy |
288,653
+177,314
| +159% | +$1.36M | ﹤0.01% | 2854 |
|
|
2018
Q4 | $835K | Buy |
111,339
+12,242
| +12% | +$89.7K | ﹤0.01% | 3420 |
|
|
2018
Q3 | $991K | Buy |
+99,097
| New | +$1.15M | ﹤0.01% | 3471 |
|
Northern Trust's TBIO Position: Q3 2021 in Review
Northern Trust sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 698,620 shares — an estimated $19.2M sold.
Northern Trust first reported a position in TBIO in Q3 2018 and held it in 12 quarters. The position peaked at $19.2M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.
- Northern Trust reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
- Northern Trust sold 698,620 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $19.2M.
- Northern Trust first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
- Northern Trust's Translate Bio, Inc. Common Stock position peaked at $19.2M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.
Based on Northern Trust's 13F filing for Q3 2021, filed 15 Nov 2021.